<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878433</url>
  </required_header>
  <id_info>
    <org_study_id>18-PP-02</org_study_id>
    <nct_id>NCT03878433</nct_id>
  </id_info>
  <brief_title>Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.</brief_title>
  <acronym>Glisodin</acronym>
  <official_title>Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity. A Prospective Randomized Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxidative stress has been reported to play a role in melasma pathophysiology. The objective
      of the study is to compare oral superoxide dismutase (GLISODin) to placebo, in combination to
      sunscreen to decrease melasma severity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of melasma</measure>
    <time_frame>At baseline and at 12 weeks</time_frame>
    <description>Change from Baseline of the Modified Melasma Area and Severity Index (mMASI) total score at 12 months. The MASI is 0 à 24 : Front 0.3(D)(A)+ right malar 0.30(D)(A)+ left malar 0.30(D)(A)+ chin 0.1(D)(A)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patient: VAS (Visual Analog Scale)</measure>
    <time_frame>At baseline and at 12 weeks</time_frame>
    <description>Change from Baseline of quality of life at 12 months (Visual Analog Scale with a graduation from 0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of the patients: VAS (Visual Analog Scale)</measure>
    <time_frame>At baseline and at 12 weeks</time_frame>
    <description>Change from Baseline of satisfaction of the patients total score at 12 months (Visual Analog Scale with a graduation from 0 to 10)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glisodin : 2 capsules of GliSODin, 500mg of GliSODIn per day. Preferably to take in the morning during breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Drug</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules of PLacebo, 500mg of Placebo per day. Preferably to take in the morning during breakfastbo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glisodin</intervention_name>
    <description>500 mg/day between 12 weeks</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months</description>
    <arm_group_label>No Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed melasma in adult patient

          -  signed inform consent

        Exclusion Criteria:

          -  Pregnant women

          -  Other pigmentary disorder of the afce

          -  Use of depigmentant agent in the month before the inclusion

          -  Use of topical steroid, tretinoin, hydroquinone in the month before the inclusion

          -  Coeliac disease or allergy to gluten
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Passeron Thierry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatologie, CHU de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Passeron Thierry, PhD</last_name>
    <phone>+33492034688</phone>
    <email>passeron.t@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Glenet stéphane, Md</last_name>
    <phone>+33492039220</phone>
    <email>crc@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Nice - Dermatology</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritime</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Passeron Thierry, PhD</last_name>
      <phone>+33492034688</phone>
      <email>passeron.t@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Glenet Stéphane, Ph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Passeron Thierry, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>May 16, 2019</last_update_submitted>
  <last_update_submitted_qc>May 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

